Related Experiment Videos
[Autoantibodies against the complement component C1q in systemic lupus erythematosus]
U Antes1, H P Heinz, K Hartung
1Institut für Medizinische Mikrobiologie, Johannes Gutenberg Universität Mainz.
Klinische Wochenschrift
|November 9, 1990
Summary
Autoantibodies against the collagen-like portion of bound C1q are prevalent in systemic lupus erythematosus (SLE). These autoantibodies correlate with disease activity markers and are the primary component of C1q-binding IgG in SLE patients.
Area of Science:
- Immunology
- Rheumatology
- Complement System
Background:
- Autoantibodies against C1q are found in nearly half of systemic lupus erythematosus (SLE) patients.
- These autoantibodies target the collagen-like region of C1q, specifically when C1q is bound, not in fluid phase.
Purpose of the Study:
- To investigate the nature and significance of autoantibodies against C1q in SLE.
- To determine if these autoantibodies are directed against bound C1q or immune complexes.
Main Methods:
- Analysis of sera from SLE patients for autoantibodies against C1q.
- Utilizing a C1q-Solid-Phase-Binding-assay to detect IgG binding.
- Assessing correlations with disease markers like dsDNA-antibodies and complement activity (CH50).
Main Results:
- Autoantibodies against the collagen-like portion of bound C1q were detected in 49.4% of SLE sera.
- These autoantibodies correlate with high dsDNA-antibody titers, low CH50, and low C1q levels.
- The primary component of C1q-binding IgG in SLE was identified as autoantibodies against bound C1q, not immune complexes.
Conclusions:
- Autoantibodies targeting the collagen-like portion of bound C1q are a key feature of SLE.
- These autoantibodies are significant indicators of disease activity and complement consumption in SLE.